Radiofrequency Ablation for Early Superficial Flat Esophageal Squamous Cell Neoplasia: A Comprehensive Review

Table 2

Outcomes of RFA for ESCN.

First author	Year	Mean or median (IQR) number of RFA	CR rate	Defined CR duration (m)	Recurrence (%)	Complications
						Stricture rate	Mean or median (IQR) number of dilation	Perforation	Bleeding/hematoma	Laceration
Pouw [44]	2008	1	100%	4	0	0	—	0	0	0
Becker [38]	2011	1.7	100%	10^†	0	0	—	0	0	0
Vilsteren [34]	2011	2 (1-3)	100%	2 months after last treatment	0	23%	3 (1-12)	1	1	2
Bergman [35]	2011	1.7	97%	12	1 (3%)	14%	2.5 (2-4)	0	0	1
Haidry [41]	2013	1 (1-3)	50%	12	10 (50%)	20%	2.5	0	2	1
Wang [45]	2014	1 (1-2)	85.7%	6	1 (14.3%)^‡	28.6%	5 (NR)	0	1	0
Wang [8]	2015	NR	94.4%	12	1 (5.6%)	22.2%	5.5 (NR)	0	0	0
He [39]	2015	1.9	84%	12	15 (16%)	21%	4 (2-6)	0	1	4
Wang [46]	2016	NR	93%	12	NR	17%	5	0	1	1
Wang [43]	2017	NR	100%	12	0	0	—	0	2	1
Wang [26]	2018	1 (1-2)	86%	12	6 (20%)	14%	3 (2-8)	0	2	1
Yu [40]	2019	1.9	86%	60	11 (14%)	21%	NR	0	0	0

RFA: radiofrequency ablation; ESCN: esophageal squamous cell neoplasia; IQR: interquartile range; CR: complete remission; NR: not reported. ^†No specific CR duration was defined. All patients had achieved CR during a follow-up of 10-28 month. ^‡This patient was not eligible for further treatment for other severe clinical conditions.